Drug discovery firm Synairgen’s (LON: SNG) shares are soaring on Wednesday after the company announced the first patient has been dosed in the UK in its global SG018 trial evaluating it’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.
The first patient received the SNG001 treatment at a hospital in Hull on Tuesday.
The treatment involves patients inhaling the interferon-beta protein to stimulate the body to fight off the coronavirus infection.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Synairgen appointed Parexel Biotech, to help conduct the Phase 3 trial and several UK sites have now been initiated, with other locations in the US and the EU expected to follow.
The trial has been deemed an Urgent Public Health study by the National Institute for Health Research in the UK while in the US SNG001 has been granted Fast Track status from the FDA.
The study is being conducted in approximately 20 countries, enrolling up to 610 patients who require supplemental oxygen.
“We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective,” commented Richard Marsden, Synairgen’s CEO.
“We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis,” added Marsden.
Synairgen shares rose to highs of 180p following the news. They are currently trading at 168p, up 9.35% on the day.
